Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCURY trial of inebilizumab in autoimmune hepatitis
NL-OMON61602Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune hepatitis (AIH) comparing Inebilizumab with Placebo (2 arms). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
inebilizumab
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NL-OMON61602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61602.